Stifel Financial Corp Buys 5,890 Shares of 10x Genomics, Inc. (NASDAQ:TXG)

Stifel Financial Corp boosted its position in 10x Genomics, Inc. (NASDAQ:TXG) by 56.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 16,369 shares of the company’s stock after acquiring an additional 5,890 shares during the quarter. Stifel Financial Corp’s holdings in 10x Genomics were worth $370,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. ARK Investment Management LLC lifted its holdings in shares of 10x Genomics by 15.4% in the 3rd quarter. ARK Investment Management LLC now owns 10,750,345 shares of the company’s stock worth $242,743,000 after acquiring an additional 1,436,582 shares during the last quarter. Point72 Asset Management L.P. purchased a new position in 10x Genomics in the 3rd quarter worth $27,778,000. Deerfield Management Company L.P. Series C bought a new stake in 10x Genomics in the second quarter worth $11,612,000. FMR LLC boosted its position in 10x Genomics by 2.7% during the third quarter. FMR LLC now owns 13,367,979 shares of the company’s stock valued at $301,849,000 after buying an additional 357,470 shares during the period. Finally, Algert Global LLC grew its stake in shares of 10x Genomics by 214.5% during the third quarter. Algert Global LLC now owns 370,958 shares of the company’s stock valued at $8,376,000 after buying an additional 252,994 shares during the last quarter. Hedge funds and other institutional investors own 84.68% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. Stephens reiterated an “overweight” rating and set a $30.00 price target on shares of 10x Genomics in a report on Thursday, October 10th. UBS Group lowered their price objective on shares of 10x Genomics from $25.00 to $20.00 and set a “neutral” rating for the company in a research note on Wednesday, October 30th. Canaccord Genuity Group cut their target price on 10x Genomics from $32.00 to $20.00 and set a “buy” rating on the stock in a research note on Thursday, October 10th. Barclays lowered their price target on 10x Genomics from $21.00 to $19.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Finally, The Goldman Sachs Group dropped their target price on shares of 10x Genomics from $16.00 to $14.00 and set a “sell” rating for the company in a research report on Wednesday, October 30th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $25.14.

10x Genomics Price Performance

NASDAQ TXG opened at $14.59 on Friday. 10x Genomics, Inc. has a 1-year low of $12.95 and a 1-year high of $57.78. The stock has a market capitalization of $1.77 billion, a price-to-earnings ratio of -9.54 and a beta of 1.84. The business’s fifty day moving average price is $15.19 and its 200-day moving average price is $18.43.

10x Genomics (NASDAQ:TXG) last issued its quarterly earnings data on Tuesday, October 29th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.04. The firm had revenue of $151.65 million during the quarter, compared to the consensus estimate of $158.84 million. 10x Genomics had a negative net margin of 28.93% and a negative return on equity of 25.07%. The company’s revenue for the quarter was down 1.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.51) EPS. Equities research analysts anticipate that 10x Genomics, Inc. will post -1.4 EPS for the current year.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.